Novo Nordisk Misled USPTO, Federal Circuit Rules

Law360, New York (October 6, 2005, 12:00 AM EDT) -- Novo Nordisk misled the patent office when it applied for a patent for a human growth hormone, the Federal Circuit ruled in a decision that will derail the company’s bid to keep a generic version of the hormone out of the U.S.

Novo Nordisk sued its generics rivals, Israel-based Teva Pharmaceuticals USA and New Jersey-based Bio-Technololgy General Corp. in April 2002 in the U.S. District Court for the District of Delaware, asserting its patent for using recombinant DNA to create hGH proteins in E.Coli bacteria....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.